Literature DB >> 28289511

Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period).

Mohamed Abdel Wahab1, Ehab El Hanafy1, Ayman El Nakeeb1, Mahmoud Abdelwahab Ali1.   

Abstract

AIM: To evaluate the clinicopathological features and the surgical outcomes of patients with fibrolamellar hepatocellular carcinoma (FL-HCC) over a 15-year period.
METHODS: This is a retrospective study including 22 patients with a pathologic diagnosis of FL-HCC who underwent hepatectomy over a 15-year period. Tumor characteristics, survival and recurrence were evaluated.
RESULTS: There were 11 male and 11 female with a median age of 29 years (range from 21 to 58 years). Two (9%) patients had hepatitis C viral infection and only 2 (9%) patients had alpha-fetoprotein level > 200 ng/mL. The median size of the tumors was 12 cm (range from 5-20 cm). Vascular invasion was detected in 5 (23%) patients. Four (18%) patients had lymph node metastases. The median follow up period was 42 mo and the 5-year survival was 65%. Five (23%) patients had a recurrent disease, 4 of them had a second surgery with 36 mo median time interval. Vascular invasion is the only significant negative prognostic factor.
CONCLUSION: FL-HCC has a favorable prognosis than common HCC and should be suspected in young patients with non cirrhotic liver. Aggressive surgical resection should be done for all patients. Repeated hepatectomy should be considered for these patients as it has a relatively indolent course.

Entities:  

Keywords:  Common hepatocellular carcinoma; Fibrolamellar hepatocellular carcinoma; Pathology of fibrolamellar hepatocellular carcinoma; Recurrence after resection fibrolamellar hepatocellular carcinoma; Survivalefter resection fibrolamellar hepatocellular carcinoma

Year:  2017        PMID: 28289511      PMCID: PMC5329705          DOI: 10.4240/wjgs.v9.i2.61

Source DB:  PubMed          Journal:  World J Gastrointest Surg


Core tip: Fibrolamellar hepatocellular carcinoma (FL-HCC) has conventionally been considered to be a histologic variant of HCC, with distinct clinicopathologic features. Many series have mentioned that FL-HCC is less aggressive than conventional HCC. However, other studies have failed to confirm the observation of a better outcome in FL-HCC. Our study shows that FL-HCC has a favorable prognosis than common HCC and should be suspected in young patients with non cirrhotic liver. Aggressive surgical resection should be done for all patients. Repeated hepatectomy or excision of recurrent disease should be considered for these patients as it has a relatively indolent course.

INTRODUCTION

Fibrolamellar hepatocellular carcinoma (FL-HCC) has conventionally been considered to be a histologic variant of hepatocellular carcinoma (HCC), with distinct clinicopathologic features. It is a rare primary hepatic malignancy that was first described as a pathological variant of HCC by Edmondson[1] in 1956. FL-HCC is usually well circumscribed masses characterized by polygonal hepatic cells with deeply eosinophilic cytoplasm and abundant fibrous stroma arranged in thin parallel bands. On gross examination, there is a central scar which resulted from coalesced lamellar bands of fibrosis[2]. The etiology of FL-HCC remains unclear. It typically occurs in normal livers without underlying liver fibrosis or cirrhosis[3]. In contrast to HCC which usually found in the presence of cirrhosis or chronic hepatitis[4]. FL-HCC has been reported to occur in association with focal nodular hyperplasia a type of benign liver lesion[5,6]. Some suggest that FHN may be a benign precursor lesion to FL-HCC as both diseases share several features: They tend to present in younger patients, and in the setting of normal liver parenchyma. Pathologically both have as a stellate central scar on imaging studies and copper accumulation on histological examination[6,7]. Many series have mentioned that FL-HCC is less aggressive than conventional HCC[8-10]. However, other studies have failed to confirm the observation of a better outcome in FL-HCC[11-13]. Other studies reported that the survival was similar between common HCC and FL-HCC, and that may be related to the higher resectability rate which improve the survival of patients with FL-HCC[12,14]. The aim of this study was to evaluate the clinicopathological features and the surgical outcomes of patients with FL-HCC who were referred to our tertiary referral center over a 15-year period.

MATERIALS AND METHODS

This is a retrospective study of patients underwent hepatectomy for a pathologic diagnosis of FL-HCC over an 15-year period between February 1999 to February 2014, in gastroenterology surgical center, Mansoura University, Egypt. A total of 22 patients was diagnosed and underwent hepatectomy during this period. The diagnosis of FL-HCC was made depending on its histological and pathological characteristics by an independent pathologic team. All patients were subjected to clinical assessment; laboratory investigation and imaging work up including: Ultrasonography, Enhanced computed tomography and MRI imaging study to evaluate the extent of the tumor, vascular involvement and lymph node affection. Clinicopathological parameters, including gender and age of patients; location, size and number of the tumor; safety margins; vascular invasion; lymph node metastasis status; operative details; morbidity and mortality; and survival and recurrence were collected. The parenchymal disease of the liver is defined as hepatitis C antibody and/or hepatitis B surface antigen was present. Safety margin is defined as complete tumor excision after surgical treatment proved by pathologic examination of the resected margins. Patients with synchronous malignancies were excluded from the study. Non of our patients underwent preoperative portal vein embolization or chemoembolization and they did not received adjuvant treatment. Clinical staging of the tumor was performed using the American Joint Committee on Cancer staging criteria[15]. The extent of hepatic resection was defined according to the Brisbane 2000 Terminology of Liver Anatomy and Resections[16]: Right hepatectomy involves resection of segments V-VIII, whereas left hepatectomy involves resection of segments (II-IV). Extended right hepatectomy involves resection of segments IV-VIII, whereas extended left hepatectomy involves resection of segments (II-IV, V, VIII). All these resection may or may not involve segment I. Most of liver resections were performed with selective vascular inflow occlusion. However, intermittent clamping was used in selected patients to avoid ischemia of the remnant liver. Liver transsection was performed using harmonic scalpel, ultrasonic dissector. Follow-up was obtained in the out-patient clinic by personal contact with the patients.

Survival analysis

Log-rank test and Kaplan-Meier curves were used for survival analysis. For continuous variables, descriptive statistics were calculated and were reported as median. Categorical variables were described using frequency distributions. Mortality was defined as death occurring in the hospital or within 30 d. Significance was defined as P < 0.05.

RESULTS

Twenty two patients with FL-HCC were diagnosed in our retrospective data base. All our patients underwent partial hepatectomy over a 15-year period. There were 11 male and 11 female with a median age of 29 years (range from 21 to 58 years). Two patients (9%) had liver cirrhosis due to hepatitis C viral infection while the remaining patients had a normal liver, and only 2(9%) patients had high AFP levels (> 200 ng/mL) (Table 1). In comparison to HCC, patients with common HCC were evaluated at our center[17], it was predominantly in male, the mean age was 54.8 ± 9.2 years, 100% had cirrhotic liver and AFP levels were elevated in all patients. FL-HCC represents about 3% of patients with hepatic malignancies (1260 patients) during the study period.
Table 1

Patient demographics

FL-HCC (n = 22)
Median age, years (range)29 yr (21 to 58)
Male/female11/11 (50%:50%)
Hepatitis or cirrhosis2 (9%)
Elevated AFP (> 200 ng/mL)2 (9%)

FL-HCC: Fibrolamellar hepatocellular carcinoma; AFP: Alpha-fetaprotein.

Patient demographics FL-HCC: Fibrolamellar hepatocellular carcinoma; AFP: Alpha-fetaprotein. Vague abdominal pain was the most common presentation, other were asymptomatic and discovered incidentally during physical examination or routine imaging work up. These tumors are well circumscribed, large and often have areas of hypervascularitywith a central scar Figure 1. Figure 2 shows FL-HCC at left liver lobe while Figure 3 demonstrates a different CT scans for FL-HCC in the right liver lobe.
Figure 1

Large right lobe fibrolamellar hepatocellular carcinoma.

Figure 2

Fibrolamellar hepatocellular carcinoma left lobe.

Figure 3

Fibrolamellar hepatocellular carcinoma right lobe.

Large right lobe fibrolamellar hepatocellular carcinoma. Fibrolamellar hepatocellular carcinoma left lobe. Fibrolamellar hepatocellular carcinoma right lobe.

Surgery and pathology

The type of hepatic resection for our 22 patients is shown in Table 2. Seventy three percent of cases required hepatectomy and 18% needed extended hepatectomy to excise their tumors. Multiple primary tumors were present in 3 patients. The median size of the tumors was 12 cm (range from 5-20 cm). Vascular invasion was detected in 5 (23%) patients. Four of those patients had microscopic vascular invasion, and one had microscopic invasion of the right hepatic vein. The safety margin was invaded in 2 (9%) patients who might be due to presence of the tumor closer tovascular structures which couldn’t be resectable. Four (18%) patients had lymph node metastases.
Table 2

Tumor characteristics’ and treatment features n (%)

FL-HCC (n = 22 )
Number
Single19 (86)
Multiple3 (14)
Size (cm)Median 12 cm (range, 5-20 )
Location9 right, 10 left, 3 bilateral
Hepatic resection
Hepatectomy16 (73)
Extended hepatectomy4 (18)
Localized resection2 (9)
Stage
I10 (45)
II5 (23)
III7 (32)
IV0
Nodal metastases4 (18)
Vascular invasion5 (23)
Positive safety margin2 (9)
Repeated hepatectomy4 (18)

FL-HCC: Fibrolamellar hepatocellular carcinoma.

Tumor characteristics’ and treatment features n (%) FL-HCC: Fibrolamellar hepatocellular carcinoma. In this study, 5 patients had a recurrent disease.Four patients had a second surgery with 36 mo median time interval. Three patients had a repeated liver resection (including both patients with microscopic invasion of resection margins and 1 patient with vascular invasion) and one patient underwent resection of large retro-caval lymph node (Figure 4). The last patient had peritoneum dissemination and nothing was done for him. The median survival was 28 mo after the second operation in these patients. There was no hospital mortality.
Figure 4

Large retro-caval lynph node 2-year after resection fibrolamellar hepatocellular carcinoma.

Large retro-caval lynph node 2-year after resection fibrolamellar hepatocellular carcinoma.

Overall survival

The median overall survival in our 22 patients was 88 mo and the 5-year survival was 65%. The median follow up period was 42 mo. In our experience of hepatic resection for HCC in cirrhotic liver (n = 175), the median survival after surgical resection was 24 mo while 5-year survival was 10.7%[17]. The univariate analysis for overall survival was performed and includes the following variables: Age, gender, size and number of tumors, type of hepatic resection, vascular invasion, nodal metastases, and resection margins (Table 3). The two patients with positive microscopic margins developed a recurrent disease. Although radically resected patients have a prolonged survival (87 mo vs 72 mo) it is not reach a statistical significance. Only vascular invasion was significant.
Table 3

Clinicopathologic features and survival in fibrolamellar carcinoma (figures in parenthesis reflect percentages)

Factorn (%)Overall survival (mo)P value
Age (yr)
< 4016 (73)86
≥ 406 (27)720.4
Gender
Female11 (50)84
Male11 (50)790.6
Tumor size (cm)
< 108 (36)82
≥ 1014 (64)760.3
Number
119 (86)89
> 13 (14)770.2
Hepatic resection
Hepatectomy16 (73)86
Extended hepatectomy4 (18)77
Localized resection2 (9)790.62
Nodal metastases
Negative18 (82)88
Positive4 (18)780.09
Vascular invasion
Absent17 (77)92
Present5 (23)580.03
Safety margin
Negative20 (91)87
Positive2 (9)720.08
Clinicopathologic features and survival in fibrolamellar carcinoma (figures in parenthesis reflect percentages) In our study, we have 8 patients with greater than 5-years follow up. Of these patients, 4 died of disease at 63, 67, 74 and 88 mo. Four patients were alive at 65-92 mo after surgery with no evidence of a recurrent disease.

DISCUSSION

FL-HCC has been considered to be a histologic variant of HCC, with distinctive morphological and clinical setting. This study confirms the distinctive clinicopathological finding of other studies that FL-HCC were larger in size than conventional HCC, affects young patients with no sex predilection and occurs in the healthy liver in absence of parenchymal disease or cirrhosis and without elevation of AFP level (Table 4)[18-21]. Elevations in AFP levels are uncommon with less than 10% of patients have AFP levels greater than 200 ng/mL[21]. In this study, only 2 patients (9%) had high AFP level (> 200 ng/mL).
Table 4

Published series on fibrolamellar hepatocellular carcinoma

Ref.nAgeMale:femaleCirrhosis/ hepatitisAFP elevatedMedian size (cm)> 1 tumorPositive nodeVascular invasionInitial operationRepeat operationMedian f/u5 yr survivalPrognostic factor
Hemming et al[18], 1997103150:50NR10%820%20%NRPhx 100%50%10170%NR
El-Gazzaz et al[19], 2000202765:350% hep B0%1420%30%55%Phx 55% OLT 45%NR2550%NONE
Kakar et al[20], 2005202753:270%3/13 (23%)< 10 31% ≥ 10 69%10%35%NRPhx 100%NRNR62%Metastasis at presentation
Stipa et al[21], 2006282843:570%7%911%50%36%Phx 100%61%3476%Positive LN
Present study222950:509%/hepc9%1213%18%23%Phx 100%18%4265%Vascular invasiom

Hep: Hepatitis; AFP: Alpha-fetoprotein elevated (> 200 ng/mL); Phx: Partial hepatectomy; NR: Not reported; f/u: Follow up.

Published series on fibrolamellar hepatocellular carcinoma Hep: Hepatitis; AFP: Alpha-fetoprotein elevated (> 200 ng/mL); Phx: Partial hepatectomy; NR: Not reported; f/u: Follow up. FL-HCC occurs in normal livers without underlying liver fibrosis or cirrhosis[3]. Pinna 1997, reported that 6% of his patients were hepatitis C positive and 7% had cirrhotic liver[10]. In our study, 2 patients (9%) were hepatitis C antibody positive, this may be attributed to high prevalence of hepatitis C virus in our community. Preoperatively, FL-HCC can be diagnosed by CT scan and MRI imagingcharacteristicas these tumors are usually heterogenous with areas of hypervascularity. Preoperative biopsy was avoided and our patients underwent surgery without biopsy which was reserved for patients who are unresectable. Ichikawa et al[22] 1999 reported that FL-HCC had 68% calcification, 65% abdominal lymphadenopathy and 71% central scar. Surgical resection is the only hope for these patients which should be done whenever possible. Our patients had 73% hepatectomy, 18% extended hepatectomy, while only 9% needed localized resection. The 5-year survival was 65% after resection, which was comparable to the 50%-70% 5-year survival rates in other reported studies (Table 4)[18-21]. Several factors have been identified in the surgical studies of FL-HCC that can predict worse prognosis. More than one tumor, metastasis at presentation, vascular invasion and positive lymph nodes[10,12,20,21] have been identified to be a negative prognostic factors. In this study, vascular invasion is the only significant negative prognostic factor after resection. Our patients have a low rate of lymph node metastasis (18%) compared to other series which range from 20%-50% (Table 4). This may be related to different tumor biology and the presence of liver cirrhosis in 9% of patients which may delay lymphatic metastases due to inhibition lymphatic outflow from the liver. On our published study on common HCC[17], lymph node metastases were found on only 8 from 175 patients (8%) this may confirm the previous data. Despite the relatively indolent tumor biology of FL-HCC, it recurs after surgical resection. The site of recurrences includes the liver, regional lymph nodes, peritoneum, and lung[23]. Some authors recommend resection of a recurrent disease due to its indolent course and absence of alternative treatment option[2]. Four patients (18%) underwent a second surgery for a recurrent disease. Three patients underwent hepatic resection while one patient underwent resection of large retro-caval lymph node. This rate is lower than the reports 50%-61% in the other series[18,21]. However, the median survival was 28 mo after the second operation. The aggressiveness and outcomes of FL-HCC vary significantly between previously published series. Some studies reported that FL-HCC is less aggressive than conventional HCC[8-10,24,25]. Other series reported that survival of FL-HCC was similar with common HCC[12,14] while other pathology and hepatology texts mention that it is associated with favorable prognosis[26-29]. Kakar et al[20], 2005 reported that FL-HCC is an aggressive tumor and nearly that half of patients develops lymph node or distant metastasis. In our study, the FL-HCC has an indolent course than common HCC, better 5-year survival can be reached in absence of vascular invasion and positive safety margins. In conclusion, FL-HCC has a favorable prognosis than common HCC and should be suspected in young patients with non cirrhotic liver. Aggressive surgical resection should be done for all patients. Repeated hepatectomy or excision of recurrent disease should be considered for these patients as it has a relatively indolent course.

ACKNOWLEDGMENTS

We thank all staff members of gastroenterology center.

COMMENTS

Background

Fibrolamellar hepatocellular carcinoma (FL-HCC) has conventionally been considered to be a histologic variant of hepatocellular carcinoma (HCC), with distinct clinicopathologic features. It is a rare primary hepatic malignancy. The etiology of FL-HCC remains unclear. It typically occurs in normal livers without underlying liver fibrosis or cirrhosis. In contrast to HCC which usually found in the presence of cirrhosis or chronic hepatitis. Some suggest that FHN may be a benign precursor lesion to FL-HCC as both diseases share several features: they tend to present in younger patients, and in the setting of normal liver parenchyma. The prognosis of FL-HCC is differ from common HCC.

Research frontiers

Many series have mentioned that FL-HCC is less aggressive than conventional HCC. However, other studies have failed to confirm the observation of a better outcome in FL-HCC. Other studies reported that the survival was similar between common HCC and FL-HCC, and that may be related to the higher resectability rate which improve the survival of patients with FL-HCC. The aim of this study was to evaluate the clinicopathological features and the surgical outcomes of patients with FL-HCC who were referred to their tertiary referral center over a 15-year period.

Innovations and breakthroughs

The epidemiology, surgical management and outcomes for patients with FL-HCC differs from one area of the world to another. The authors have a published data and experience from Western, Eastern and European countries. However, The authors have a little data from Middle East countries, and here they represent their work from a large gastroenterology and transplantation center in Egypt in dealing with patients with FL- HCC over a 15 years period.

Applications

The surgery of FL-HCC is differs from HCC as it occurs in non-cirrhotic liver, so aggressive surgery was adopted for more radical surgery even for a recurrent disease.

Terminology

Clinical staging of the tumor was performed using the American Joint Committee on Cancer (AJCC) staging criteria. The extent of hepatic resection was defined according to the Brisbane 2000 Terminology of Liver Anatomy and Resections: Right hepatectomy involves resection of segments V-VIII, whereas left hepatectomy involves resection of segments (II-IV). Extended right hepatectomy involves resection of segments IV-VIII, whereas extended left hepatectomy involves resection of segments (II-IV, V, VIII).

Peer-review

This manuscript seems worth to be reported, because clinicopathological features of FL-HCC are clearly written.
  24 in total

Review 1.  Fibrolamellar cancer of the liver.

Authors:  H J Hodgson
Journal:  J Hepatol       Date:  1987-10       Impact factor: 25.083

Review 2.  Fibrolamellar hepatocellular carcinoma in children and adolescents.

Authors:  Howard M Katzenstein; Mark D Krailo; Marcio H Malogolowkin; Jorge A Ortega; Wenchun Qu; Edwin C Douglass; James H Feusner; Marleta Reynolds; John J Quinn; Kurt Newman; Milton J Finegold; Joel E Haas; Martha G Sensel; Robert P Castleberry; Laura C Bowman
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

Review 3.  Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation.

Authors:  J K McLarney; P T Rucker; G N Bender; Z D Goodman; N Kashitani; P R Ros
Journal:  Radiographics       Date:  1999 Mar-Apr       Impact factor: 5.333

4.  Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases.

Authors:  T Ichikawa; M P Federle; L Grazioli; J Madariaga; M Nalesnik; W Marsh
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

5.  Fibrolamellar hepatoma.

Authors:  D M Nagorney; M A Adson; L H Weiland; C D Knight; S R Smalley; A R Zinsmeister
Journal:  Am J Surg       Date:  1985-01       Impact factor: 2.565

6.  Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma.

Authors:  G El-Gazzaz; W Wong; M K El-Hadary; B K Gunson; D F Mirza; A D Mayer; J A Buckels; P McMaster
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

Review 7.  Fibrolamellar hepatoma.

Authors:  M T Ruffin
Journal:  Am J Gastroenterol       Date:  1990-05       Impact factor: 10.864

8.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

9.  Neurotensin secretion by fibrolamellar carcinoma of the liver.

Authors:  N A Collier; K Weinbren; S R Bloom; Y C Lee; H J Hodgson; L H Blumgart
Journal:  Lancet       Date:  1984-03-10       Impact factor: 79.321

10.  Hepatocellular carcinoma: importance of histologic classification as a prognostic factor.

Authors:  W J Wood; M Rawlings; H Evans; C N Lim
Journal:  Am J Surg       Date:  1988-05       Impact factor: 2.565

View more
  6 in total

1.  Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis.

Authors:  D Kyziridis; A Kalakonas; K Zarambouka; C Hristakis; Antonios-Apostolos K Tentes
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.

Authors:  Sakti Chakrabarti; Sri Harsha Tella; Anuhya Kommalapati; Brandon M Huffman; Siddhartha Yadav; Irbaz Bin Riaz; Gaurav Goyal; Kabir Mody; Mitesh Borad; Sean Cleary; Rory L Smoot; Amit Mahipal
Journal:  J Gastrointest Oncol       Date:  2019-06

3.  Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection.

Authors:  Sebastian Mafeld; Jeremy French; Dina Tiniakos; Beate Haugk; Derek Manas; Peter Littler
Journal:  Cardiovasc Intervent Radiol       Date:  2018-02-21       Impact factor: 2.740

Review 4.  Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.

Authors:  Walaa Abdelhamed; Mohamed El-Kassas
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

Review 5.  A Multidisciplinary Approach to the Management of Fibrolamellar Carcinoma: Current Perspectives and Future Prospects.

Authors:  Georgios Polychronidis; Anastasia Murtha-Lemekhova; Juri Fuchs; Evdokia Karathanasi; Katrin Hoffmann
Journal:  Onco Targets Ther       Date:  2022-10-03       Impact factor: 4.345

Review 6.  Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions.

Authors:  Sara Bedrose; Marilyne Daher; Lina Altameemi; Mouhammed Amir Habra
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.